NEW CLINICAL EFFICACY RESULTS DEMONSTRATE THAT GFT505:
-
REDUCES GLOBAL CARDIOVASCULAR RISK FACTORS IN PREDIABETIC PATIENTS
WITH IMPAIRED GLUCOSE TOLERANCE
-
DECREASES FASTING GLUCOSE LEVELS AND IMPROVES INSULIN SENSITIVITY
-
HAS A POSITIVE IMPACT ON LIPID PARAMETERS (TRIGLYCERIDES AND
CHOLESTEROL)
-
HAS ANTI-INFLAMMATORY EFFECTS
GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical
company at the forefront of drug discovery and development, focusing on
the early diagnosis and preventive treatment of cardiometabolic and
neurodegenerative diseases, today announces positive results from a
recently completed clinical trial demonstrating the activity of GFT505
on glucose homeostasis. Results from the clinical trial (GFT505-2094)
clearly demonstrate the potential of the drug candidate to reduce global
cardiovascular risk in prediabetic patients who suffer from impaired
fasting plasma glucose, impaired glucose tolerance, and abdominal
obesity.
Following treatment with GFT505 (80mg/day) for 28-days, the main
objective of the study which was demonstration of efficacy of the
compound on glucose homeostasis was attained. GFT505 led to a
significant reduction in fasting plasma glucose levels in the treated
group in comparison to the placebo treated group (-5% vs placebo,>
In addition to the effects of GFT505 on glucose homeostasis and parallel
to results from the previous study (GFT505-2083), the new results from
the GFT505-2094 study clearly reaffirm the beneficial effects of the
compound on plasma lipids and demonstrate an additional effect on LDL-C.
Patients treated with GFT505 had a significant reduction of bad
cholesterol (LDL-C, -11% vs placebo,>
Taken together, the effects of GFT505 on plasma glucose, lipids, and
inflammation, are expected to strongly reduce the risk of macrovascular
events and microvascular complications found in prediabetic patients.
The present study also confirms the favorable efficacy/safety ratio of
GFT505, considering that no specific side effects were observed between
the treated and placebo groups. In particular, treatment with GFT505, in
contrast to fenofibrate, did not increase the level of circulating
homocysteine which is considered a marker of cardiovascular risk.